Platinum based chemoradiotherapy is the standard of care for inoperable non-small cell lung cancer (NSCLC). With evidence that NSCLC can have a dose dependent response with stereotactic ablative radiotherapy (SABR), we hypothesize that a SABR boost on residual tumor treated with chemoradiotherapy could increase treatment efficacy. The purpose of this study was to determine feasibility of such an approach.
from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2Exm3Xj
Δευτέρα 9 Απριλίου 2018
Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction che...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jCvX3K via IFTTT
-
Dental implants are now broadly used to replace missing teeth, and the presence of infectious complications is rising. Dental implant therap...
-
Indications and extent of central neck dissection for papillary thyroid cancer: An American Head and Neck Society Consensus Statement. ...
-
Abstract Purpose Accurate and real-time prediction of the lung and lung tumor deformation during respiration are important consideration...
-
Abstract Purpose of Review Our goal is to summarize the airway disease literature since September 11, 2001 (9/11), focusing on studies pub...
-
Treatment effectiveness holds considerable importance in the association between service quality and satisfaction in medical service studies...
-
Therapeutic agents designed to stimulate the immune system are now cornerstones in the treatment of metastatic melanoma. These drugs promote...
-
Coenzyme Q (CoQ) is a key component of the mitochondrial respiratory chain, but it also has several other functions in the cellular metaboli...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου